Eli Lilly | PharmaShots

Eli Lilly in Collaboration with NIAID Initiate P-III Study of LY-CoV555 to Prevent COVID-19

August 4, 2020August 4, 2020Tuba Khan

Shots: Eli Lilly initiates P-III BLAZE-2 study assessing LY-CoV555 to prevent SARS-CoV-2 infection and COVID-19 in residents and staff at long-term care facilities [Read More...]

Eli Lilly Reports Results of Jardiance (empagliflozin) in P-III EMPEROR Trial for Heart Failure Patients with Reduced Ejection Fraction with and without Diabetes

July 30, 2020July 30, 2020Shiwani Sharma

Shots: The P-III EMPEROR Trial involves assessing of Jardiance (10 mg) vs PBO in two studies EMPEROR-Reduced [NCT03057977, N=3,730] & EMPEROR-Preserved [NCT03057951, N=5,990] [Read More...]

Eli Lilly’s P-tau217 Blood Test Demonstrate High Accuracy in Diagnosis of Alzheimer’s Disease

July 29, 2020July 29, 2020Tuba Khan

Shots: The study involved 1402 patients across 3 cohorts: a) 81 patients in Arizona (34 with AD and 47 without), b) 699 in [Read More...]

Eli Lilly Amends its 2013 Agreement with Chi-Med to Commercialize Elunate (fruquintinib) in China

July 28, 2020July 28, 2020Tuba Khan

Shots: Chi-Med to receive 70%-80% of Elunate sales in the form of royalties, manufacturing costs and service payments with no upfront regarding this [Read More...]

Insights+ Exclusive: The US FDA New Drug Approvals in June 2020

July 24, 2020July 24, 2020Shiwani Sharma

The US FDA has approved multiple NDAs and BLAs in Jun 2020, leading to treatments for patients and advances in the health care [Read More...]

Eli Lilly Reports Results of Mirikizumab in P-III OASIS-2 Study to Treat Moderate to Severe Plaque Psoriasis

July 17, 2020July 20, 2020Tuba Khan

Shots: The P-III OASIS-2 study involves assessing mirikizumab vs PBO & Cosentyx (secukinumab) in 1,465 patients with mod. to sev. PsO. The patients [Read More...]

Insights+ Key Biosimilars Events of April 2020

Insights+ Key Biosimilars Events of June 2020

July 3, 2020July 3, 2020Shiwani Sharma

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be [Read More...]

QurAlis Signs a License Agreement with Eli Lilly for its ALS Therapeutic Candidates

July 1, 2020July 1, 2020Tuba Khan

Shots: QurAlis in-licenses Eli Lilly’s excitotoxicity targeted pre-clinical compounds with disease-modifying potential in ALS The collaboration allows QurAlis to foster its ALS Pipeline [Read More...]

PharmaShots Weekly Snapshot (Jun 15-19, 2020)

June 22, 2020June 29, 2020Tuba Khan

1. Ultragenyx and Kyowa Kirin’s Crysvita (burosumab) Receive the US FDA’s Approval for the Treatment of Tumor-Induced Osteomalacia Published: Jun 19, 2020 | Tags: [Read More...]